(Q37246638)

19 August 2017

1 reference

title

Donor lymphocyte infusions: the long and winding road: how should it be traveled? (English)

1 reference

19 August 2017

0 references

M Tomblyn

1

1 reference

19 August 2017

H M Lazarus

series ordinal

2

1 reference

19 August 2017

language of work or name

English

0 references

publication date

18 August 2008

1 reference

Bone Marrow Transplantation

19 August 2017

1 reference

19 August 2017

42

1 reference

19 August 2017

9

1 reference

19 August 2017

569-579

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2008.259

19 August 2017

0 references

cites work

Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

The impact of chimerism patterns and predonor leukocyte infusion lymphopenia on survival following T cell-depleted reduced intensity conditioned transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Addition of a low fixed number of CD3+ cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Minimal GVHD following in-vitro Tcell–depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Richter's syndrome after allogeneic stem cell transplantation for chronic lymphocytic leukaemia successfully treated by withdrawal of immunosuppression, and donor lymphocyte infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusion

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Successful treatment of JMML relapsed after unrelated allogeneic transplant with cytoreduction followed by DLI and interferon-alpha: evidence for a graft-versus-leukemia effect in non-monosomy-7 JMML

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Successful second allogeneic peripheral blood stem cell transplantation and donor lymphocyte infusion in patients with relapsed acute leukemia using the same donors as for the initial allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.259

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.259

1 reference

Dimensions Publication ID

19 August 2017

0 references

1 reference